Pyxis Oncology Seeks Approval to Double Authorized Shares to 380M to Cover Warrant Exercises

summarizeSummary

Pyxis Oncology is seeking stockholder approval to double its authorized common shares to 380 million, primarily to permit exercise of 49.3 million warrants issued in its recent $110 million offering. Without approval, those warrants cannot be exercised and may have no value.

check_boxKey Events · Corporate Governance and Compliance · PYXS

• Charter Amendment to Double Authorized Shares

  Proposal One seeks to increase authorized common stock from 190,000,000 to 380,000,000 shares. As of the October 8 record date, 119,583,637 shares were outstanding, with 39,698,811 reserved for options/RSUs/warrants and 3,072,366 reserved for equity plans, leaving only 27,645,186 authorized but unissued shares.

• Warrant Exercise Shortfall

  The company lacks sufficient authorized shares to permit exercise of 49,310,352 common warrants issued in the October 1 offering. If the charter amendment is not approved, these warrants cannot be exercised and may have no value.

• Contractual Meeting Obligation

  Pyxis has agreed to hold a special meeting within 60 days of the offering closing (by November 30, 2026) and to call additional meetings every 60 days thereafter until stockholder approval is obtained or the warrants are no longer outstanding.

• Special Meeting Scheduled

  The special meeting will be held virtually on November 13, 2026 at 10:00 a.m. Eastern Time. Stockholders of record as of October 8, 2026 are entitled to vote.

auto_awesomeAnalysis · PYXS · Life Sciences

Pyxis Oncology is asking stockholders to approve doubling its authorized common shares from 190 million to 380 million. The company does not currently have enough authorized shares to permit exercise of the 49.3 million common warrants issued in its October 1 offering. If stockholders do not approve the increase, those warrants cannot be exercised and may become worthless. The company has contractually agreed to hold stockholder meetings every 60 days until approval is obtained or the warrants expire. As of the record date, only 27.6 million authorized shares remain available for general corporate purposes, leaving a shortfall of roughly 21.7 million shares needed to cover the warrants alone. The special meeting is scheduled for November 13, 2026.